|By Marketwired .||
|November 22, 2012 08:20 AM EST||
NEW YORK, NY -- (Marketwire) -- 11/22/12 -- The American Journal of Preventive Medicine forecasts that by 2030 42 percent of U.S. adults could be obese, which would add approximately $550 billion to healthcare costs over that time span. There have been two anti-obesity drugs approved by the FDA in 2012 -- Arena's Belviq and VIVUS' Qsymia. Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and VIVUS, Inc. (NASDAQ: VVUS).
Access to the full company reports can be found at:
Shares of anti-obesity drug makers received a major boost Wednesday after the third largest health insurer, Aetna, said it will provide certain patients coverage for anti-obesity treatments. Cowen and Co. analyst Simos Simeonidis has stated that Aetna's announcement could soon pressure other insurers to also add coverage. The Centers for Disease Control and Prevention (CDC) earlier this year reported that 35.7 percent of U.S. adults and 16.9 percent of children (age 2 to 19) are obese.
Five Star Equities releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.
Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs for weight management, cardiovascular disease, inflammation and other disorders. The company's weight loss drug, Belviq, is currently under review by the Drug Enforcement Administration.
VIVUS is a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health for U.S., Europe and other world markets. The company recently submitted an amendment to the Risk Evaluation and Mitigation Strategy for Qsymia, which would allow dispensing through a broader range of pharmacies.
Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:
Five Star Equities